Ruxolitinib formulation for reduction of itch in atopic dermatitis
US11510923B2 · kind B2 · utility
1Cited by
4References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 4, 2020 |
| Grant date | Nov 29, 2022 |
| Priority date | — |
| Expiry date | Apr 10, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.